NICE recommends drugs for rheumatoid arthritis
The National Institute for Health and Care Excellence (NICE) has recommended adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept, all in combination with methotrexate, as options for treating rheumatoid arthritis, if the disease is severe (e.g. a disease activity score [DAS28] greater than 5.1) and the disease has not responded to intensive therapy with a combination of conventional disease‑modifying antirheumatic drugs (DMARDs). Companies must also provide certolizumab pegol, golimumab, abatacept and tocilizumab under the terms agreed in their patient access schemes. Full details of the recommendations can be found on the NICE website.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20200649
Recommended from Pharmaceutical Press